August 1, 2025Open Access

Hemoglobin and High‐Density Lipoprotein as Biomarker of Left Atrial Dilatation in Sickle Cell Disease

GFGuillaume FeugrayInserm MGMaximilien GrallCentre Hospitalier Universitaire de Rouen BGBaptiste GillardinCentre Hospitalier Universitaire de Rouen

Key Points

Left atrial dilatation was found in 61% of sickle cell disease patients, indicating potential cardiac risk.
An algorithm with hemoglobin ≤ 9.7 g/dL and HDL-C ≤ 50 mg/dL showed strong diagnostic accuracy for identifying cardiac issues.
Echocardiography was utilized to assess cardiac abnormalities in a cohort of 59 adult sickle cell disease patients.
These results emphasize the importance of biomarker-based screening in managing cardiac complications in sickle cell disease.

Abstract

ABSTRACT Sickle cell disease (SCD) is associated with cardiac remodeling, particularly left atrial dilatation, which may predict adverse cardiovascular outcomes. This study assessed cardiac abnormalities using echocardiography in 59 adult SCD patients and explored biomarkers predictive of left atrial remodeling. Left atrial dilatation was found in 61% of patients and significantly associated with hemoglobin, hemoglobin S, HDL‐C, and the atherogenic index of plasma. An algorithm combining hemoglobin ≤ 9.7 g/dL and HDL‐C ≤ 50 mg/dL showed high‐diagnostic performance. These findings support biomarker‐based screening as a useful tool in resource‐limited settings for early detection of cardiac complications in SCD. Trial Registration : ClinicalTrials.gov identifier: NCT05376046

AIに質問

Bookmark

View Full Paper